1998
DOI: 10.1016/s0165-4608(97)00390-7
|View full text |Cite
|
Sign up to set email alerts
|

Translocation (3;16)(q27;p11) in a Patient with Diffuse Large B-Cell Lymphoma Associated with the BCL-6 Gene Rearrangement

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

1998
1998
2002
2002

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 46 publications
0
4
0
Order By: Relevance
“…4 However, not only point mutations but also somatic hypermutation within germinal centers, leading to structural alterations of the Ig variable genes, may promote translocations as in the case of follicular lymphoma, endemic Burkitt's lymphoma, and certain translocations in diffuse large B-cell lymphomas, eg, t (3;14), involving the bcl-6 gene. 6,14,24,36 In this respect, non-Ig genes linked to transcriptional initiation in mutating normal germinal center B cells may also be permissible in the hypermutation process as recently found for the bcl-6 gene, which is heavily mutated in normal memory B cells but not mutated in naive human B lymphocytes. 52 The necessity of a DNA repair mechanism involved in microdeletion through error-prone repair 13 or by correcting the unmutated complementary to the mutated base 7 and their defects offers another phase of the link between somatic hypermutation of Ig variable genes and lymphoma development.…”
Section: Are Germinal Centers Pathogenic Hot Spots Of Lymphoma Develomentioning
confidence: 80%
“…4 However, not only point mutations but also somatic hypermutation within germinal centers, leading to structural alterations of the Ig variable genes, may promote translocations as in the case of follicular lymphoma, endemic Burkitt's lymphoma, and certain translocations in diffuse large B-cell lymphomas, eg, t (3;14), involving the bcl-6 gene. 6,14,24,36 In this respect, non-Ig genes linked to transcriptional initiation in mutating normal germinal center B cells may also be permissible in the hypermutation process as recently found for the bcl-6 gene, which is heavily mutated in normal memory B cells but not mutated in naive human B lymphocytes. 52 The necessity of a DNA repair mechanism involved in microdeletion through error-prone repair 13 or by correcting the unmutated complementary to the mutated base 7 and their defects offers another phase of the link between somatic hypermutation of Ig variable genes and lymphoma development.…”
Section: Are Germinal Centers Pathogenic Hot Spots Of Lymphoma Develomentioning
confidence: 80%
“…We previously showed that the majority of lymphoma cells of no. 1012 had t(3;16) as the sole chromosome abnormality, indicating that the translocation was the primary genetic abnormality in this particular case (Ichinohasama et al, 1998). In contrast, YM cells carried a t(2;18)(p11;q21) leading to the fusion between BCL2 and the IG k-light chain gene (Yonetani et al, 1998), raising the possibility that the t(3;16) was a secondary change that developed in a prelymphomatous B-cell with BCL2 translocation and was related to progression to¯orid lymphoma.…”
Section: Of Three Independent Experimentsmentioning
confidence: 83%
“…Cytogenetic and molecular analysis of YM cells revealed that the cells carried t(3;16)(q27;p11) and t(2;18)(p11;q21) involving BCL6 and BCL2, respectively (Yonetani et al, 1998 (Ichinohasama et al, 1998). The cell lines used in the present study were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) under the standard culture conditions.…”
Section: Cellsmentioning
confidence: 99%
“…Flow cytometric analysis was carried out according to the method of Ichinohasama et al 19,20 with some modifications using CYTORON ABSOLUTE TM (Ortho Diagnostic Systems, Tokyo, Japan). Antibodies used were specific for CD2 (T11; Beckman Coulter), CD3 (UCHT1; Beckman Coulter), CD4 (T4; Beckman Coulter), CD5 (Lue1; Beckton Dickinson Immunocytometry Systems, San Jose, CA, USA), CD7 (T55; Nichirei, Tokyo, Japan), CD8 (T8; Beckman Coulter), CD10 (J5; Beckman Coulter), CD13 (WM15; Pharmingen, San Diego, CA, USA), CD14 (Mo2; Beckman Coulter), CD16 (3G8; Pharmingen), CD19 (CLB‐CD19; Nichirei), CD20 (NU‐B2; Nichirei), CD33 (WH53; Pharmingen), CD34 (HPCA‐2; Beckton Dickinson), CD56 (B159; Pharmingen), HLA (human leukocyte antigen)‐DR (L243; Beckton Dickinson).…”
Section: Methodsmentioning
confidence: 99%